Results 231 to 240 of about 233,946 (332)

Epidemiology, Risk Factors and Pathophysiology of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease: An Update

open access: yesJCC Plus, Volume 1, Issue 3, May 2026.
ABSTRACT Background and Aims Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) represent a unique clinical syndrome affecting up to 80% of PSC patients, characterised by distinct epidemiological patterns, pathophysiological mechanisms and clinical outcomes that differ substantially from either condition occurring independently ...
Luisa Bertin   +7 more
wiley   +1 more source

Endovascular Thrombus Removal for Acute Iliofemoral Deep Vein Thrombosis: Analysis from a Stratified Multicenter Randomized Trial [PDF]

open access: yes, 2018
Assi, Zakaria   +17 more
core   +1 more source

Personalized Management of Cytopenias in Chronic Liver Disease: From Pathophysiology to Treatment Strategies

open access: yesJGH Open, Volume 10, Issue 5, May 2026.
ABSTRACT Thrombocytopenia and leukopenia are among the most common hematological abnormalities in patients with chronic liver disease (CLD), particularly among those with cirrhosis. Thrombocytopenia and leukopenia are associated with increased risks of bleeding, infection, treatment delay, and poor clinical outcomes.
Xiaoxiao Wang   +3 more
wiley   +1 more source

Real‐World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry

open access: yesUnited European Gastroenterology Journal, Volume 14, Issue 4, May 2026.
ABSTRACT Background Upadacitinib (UPA) is the first oral Janus kinase (JAK) inhibitor approved for the treatment of Crohn's disease (CD). Real‐world data, particularly from large nationwide cohorts, remain limited. This study aimed to evaluate the real‐world effectiveness, safety, and treatment persistence of UPA in patients with CD.
M. Iborra   +51 more
wiley   +1 more source

Japanese Clinical Practice Guidelines for Vascular Tumors, Vascular Malformations, Lymphatic Malformations, and Lymphangiomatosis 2022

open access: yesThe Journal of Dermatology, Volume 53, Issue 5, Page e257-e356, May 2026.
ABSTRACT The objective was to prepare guidelines to perform the current optimum treatment by organizing effective and efficient treatments of hemangiomas and vascular malformations, confirming the safety, and systematizing treatment, employing evidence‐based medicine techniques and aimed at improvement of the outcomes.
Yoshiaki Kinoshita   +116 more
wiley   +1 more source

Bleeding Disorders in Children With Genetic Diseases: A Narrative Review

open access: yesActa Paediatrica, Volume 115, Issue 5, Page 1015-1024, May 2026.
ABSTRACT Aim The lack of data on bleeding risk assessment in children with genetic diseases is concerning given their increased care needs and risk of haemorrhagic complications compared to the general population. Identification of haemostatic disorders is crucial for implementing preventive measures and mitigating bleeding risk.
Raphaelle Cagol   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy